Brought to you by 
Archimedes raises £65mm from new and existing investors
05 Mar 2010
Executive Summary
Archimedes Pharma (therapeutics for cancer, pain, and neurology) raised £65mm ($100mm) through its latest financing round. New investor Novo Growth Equity (managed by Novo AS) participated, along with Archimedes' major returning investor Warburg Pincus. Proceeds from the round, which is being called the largest by a private European biopharmaceuticals company in 15 years, will be used to establish operations in the US, and to globally launch Archimedes' PecFent, a fentanyl nasal spray for breakthrough cancer pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
- Nasal
- Site Specific
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Archimedes raises £65mm from new and existing investors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice